You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》聖諾醫藥(02257.HK)今起招股 一手入場費3,671.63元
阿思達克 12-20 10:42
核糖核酸(RNA)療法生物製藥商聖諾醫藥(02257.HK)公布招股內容,計劃全球發售754萬股,香港公開發售佔1成,國際發售佔9成,招股價介乎65.9至72.7元,每手50股計,一手入場費3,671.63元。該股今日(20日)起招股,周四(23日)中午截止,預期12月30日掛牌。獨家保薦人為中金公司。 公司引入昆明佳時清及健新原力製藥為基石投資者,合共認購約2,860.18萬美元公司股份。 如以招股價中位數69.3元計,料公司上市淨集約4.2億元,約57.9%擬用於撥付發展及商業化STP705;15.6%用於撥付STP707的開發;15.4%用於撥付GalNAc計劃產品,如STP122G、STP133G及STP144G,以及其他臨床前階段候選產品(倘有關研發將進一步推進專有的用於開發新型候選產品的GalAhead及PDoV-GalNAc遞送平台);7.3%用於撥付其他臨床前候選藥物的研發;3.8%用於一般企業及營運資金用途。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account